Skip to content

Aripiprazole

SGA • Last reviewed 2025-09-23

Brands: Abilify

Sources updated 2025 • 1 references

Summary

General Information

Indicated for: Schizophrenia; acute manic/mixed episodes (bipolar I); adjunct for major depressive disorder; irritability in autistic disorder; Tourette’s disorder. Second‑generation antipsychotic (SGA) Also available as a long‑acting injectable (see LAI section below).

Dosage & Administration

Typical dose range: 10–30 mg/day

Indications (label)

Schizophrenia; acute manic/mixed episodes (bipolar I); adjunct for major depressive disorder; irritability in autistic disorder; Tourette’s disorder.

View labelExact

Mechanism (brief)

Partial agonist at dopamine D2 and serotonin 5-HT1A; antagonist at 5-HT2A receptors.

Metabolism & Half‑life

  • Metabolism: CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole.
  • Half‑life: ~75 h (up to ~146 h in CYP2D6 poor metabolizers).

Therapeutic Drug Monitoring (TDM)

Recommended: No

Long‑acting injectable (LAI)

Aripiprazole monohydrate
Interval
Monthly (q4wk)
Oral overlap
Yes — typically 14 days
Site
Deltoid or gluteal

Citations

LabelDOIPMCID
Aripiprazole lauroxil
Interval
q4–8wk (varies by strength)
Oral overlap
Yes — typically 21 days (unless using Initio loading)
Site
Deltoid or gluteal

Citations

LabelLabelDOI

References